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Quorum sensing (QS) is the process through
which bacteria communicate utilizing small
diffusible molecules termed autoinducers. It
hasbeendemonstrated thatQScontrolsapleth-
oraofmicrobial processes including theexpres-
sion of virulence factors. Here we report an im-
munopharmacotherapeutic approach for the
attenuation of QS in the Gram-positive human
pathogenStaphylococcusaureus. An anti-auto-
inducer monoclonal antibody, AP4-24H11, was
elicited against a rationally designed hapten,
and efficiently inhibited QS in vitro through the
sequestration of the autoinducing peptide
(AIP)-4 produced by S. aureus RN4850. Impor-
tantly, AP4-24H11 suppressed S. aureus patho-
genicity in an abscess formation mouse model
in vivo and provided complete protection
against a lethal S. aureus challenge. These find-
ings provide a strong foundation for further in-
vestigations of immunopharmacotherapy for
the treatment of bacterial infections in which
QS controls the expression of virulence factors.
INTRODUCTION
The ability of microorganisms to coordinate their gene
expression in a population density-dependent manner
has been coined ‘‘quorum sensing’’ (QS) [1]. This chemical
exchange of information among single-cell organisms is
mediated by secreted signaling molecules termed autoin-
ducers (AI) [2]. Bacterial autoinducers can be classified
into three major chemical groups: (1) N-acyl homoserine
lactones (AHLs) that have been shown to be produced
by over 70 species of Gram-negative bacteria [3, 4], (2) oli-
gopeptides, which are generally employed by Gram-pos-
itive bacteria [5, 6], and (3) the ribose-like S-4,5-dihy-
droxy-2,3-pentanedione (DPD)/autoinducer (AI)-2, which
is utilized by both Gram-negative and -positive bacteriaChemistry & Biology 14, 1119–11and, thus, can be regarded as an interspecies QS signal-
ing molecule [7, 8].
Important biological and clinical aspects of QS include
the regulation of bacterial virulence factors [9, 10], and
hence inhibition of QS signaling could provide a promising
new strategy for the attenuation of bacterial infections [11–
13]. Indeed, small-molecule antagonists using AI analogs
have been examined in a number of QS circuits as a means
of signaling interference [14–18]. Alternatively, our labora-
tory pioneered an antibody-based strategy to inhibit AHL-
mediated QS in Gram-negative bacteria [19]. Notably, fol-
lowing our initial report, an active immunization model in
mice using an AHL-based vaccine was disclosed [20].
Ramifications arising from these studies have provided
us further impetus to evaluate immunopharmacothera-
peutic approaches targeting other bacterial QS systems.
Staphylococcus aureus is the most common cause of
hospital-acquired infections [21] including various dis-
eases ranging from skin infections and food poisoning to
life-threatening nosocomial infections. Increasing resis-
tance of S. aureus isolates to glycopeptide antibiotics,
most prominently vancomycin, is a major concern in to-
day’s intensive care units, and therefore an alternative
strategy to combat this pathogen is urgently required. Ac-
cessory gene regulator (agr) is the best-characterized QS
circuit in S. aureus. The agr system utilizes cyclic oligo-
peptides, termed autoinducing peptides (AIPs), and these
contribute to bacterial pathogenesis by orchestrating the
temporal cell density-dependent expression of virulence
genes [22]. Genes regulated by agr encode cell-surface
proteins such as protein A, coagulase, and fibronectin-
binding proteins, and secreted proteins including prote-
ases, hemolysins, toxic shock syndrome toxin 1 (TSST-
1), and enterotoxin B.
In addition, the agr QS system has also been linked to
resistance with glycopeptide antibiotics in S. aureus [23].
Notably, Novick and coworkers have demonstrated that
transient inactivation of the agr QS circuit might indeed
be sufficient to prevent the deleterious effects of certain
S. aureus infections [24]. Thus far, four different AIPs,
with varying degrees of sequence similarities, have been
identified as agr QS molecules (Figure 1) [25]. As a starting27, October 2007 ª2007 Elsevier Ltd All rights reserved 1119
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Anti-Autoinducer Antibodypoint for antibody-based interference with AIP-mediated
QS, we focused on the AIP-4 QS system and its cognate
strains RN4850 and NRS168 [16].
RESULTS AND DISCUSSION
Design and Synthesis of the AIP-4 Hapten
Based on the reported structural information of AIP-4 [26],
we designed and synthesized the hapten AP4, 5 to elicit an
anti-AIP-4 antibody immune response in mice (Figure 2).
Our reasoning for the chemical switch from the native thi-
olactone to a lactone-containing hapten was based on
a lactone’s greater aminolytic stability [27]. This strategy
ensured that the hapten conjugates remained structurally
intact during the immunization process and subsequent
immune response, thus avoiding the generation of degra-
dation products with unknown chemical and biological
properties as previously uncovered for other QS mole-
cules by our laboratory [28]. Furthermore, this substitution
was also intended to prevent a possible intramolecular
thiol exchange between the conserved thiolactone and
the pendant cysteine thiol. Therefore, Fmoc-serine(Trt)-
OH was incorporated at position 4 in place of the native
cysteine residue.
The hapten 5 was conjugated to the carrier proteins
keyhole limpet hemocyanin (KLH) and bovine serum albu-
min (BSA) via a bifunctional linker (see Figure S1 in the
Supplemental Data available with this article online).
Balb/c mice were immunized with the KLH conjugate
using standard protocols [19]. Overall, the immunizations
resulted in moderate titers (1600–3200) and, based on
ELISA analysis, 20 monoclonal antibodies (mAbs) were
prepared. The affinities of the AP4 mAbs were determined
against all four natural AIPs using competition ELISA
methodology (see Table S1). One of the mAbs, namely
AP4-24H11, possessed strong binding affinity (Kd AIP-4z
90 nM) and high specificity to AIP-4 while displaying
little crossreactivity for the other AIPs (Kd AIP-1 z 5 mM,
Kd AIP-2 R 25 mM, Kd AIP-3 R 25 mM). The ability of AP4-
Figure 1. Structures of the AIPs Used by S. aureus
The oligopeptides are cyclized posttranslationally via a thioester link-
age between the thiol moiety of the conserved (*) Cys and the carboxyl
group of the C-terminal residue.1120 Chemistry & Biology 14, 1119–1127, October 2007 ª200724H11 to discriminate between AIP-1 and AIP-4 is note-
worthy, as these two oligopeptides differ only at position
5 with an aspartic acid residue in AIP-1 and a tyrosine
moiety in AIP-4. Thus, AP4-24H11 was selected for further
biological evaluation.
AP4-24H11 Alters Expression of Virulence Factors
in S. aureus
a-Hemolysin and protein A are two major virulence factors
in S. aureus, and expression of these proteins is tightly
regulated by S. aureus signaling networks including the
AIP-based agr QS system. The agr QS system positively
regulates expression of a-hemolysin, whereas protein A
production is downregulated by QS signaling. In order to
test our rationale that anti-AIP antibodies are able to inter-
fere with QS signaling in S. aureus, we examined whether
Figure 2. Synthesis of the AP4 Hapten 5
The linear peptide was synthesized on 2-chlorotrityl resin preloaded
with Fmoc-methionine 1 using standard Fmoc chemistry employing
DIC/HOBt as coupling reagents. The N-terminal pendant cysteine
was incorporated for conjugation to a carrier protein and the short flex-
ible linker was added between the hapten and the carrier protein as
a spacer. The protected linear peptide was released from the resin us-
ing 4% trifluoroacetic acid in chloroform, which also selectively re-
moved the trityl protection group from the serine. Intramolecular lacto-
nization under dilute conditions was performed using EDC/4-DMAP,
and subsequent side-chain deprotections afforded the AP4 hapten
5. (For full details, see Experimental Procedures.)Elsevier Ltd All rights reserved
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Anti-Autoinducer Antibodythe anti-AIP-4 mAb AP4-24H11 could modulate the ex-
pression of a-hemolysin and protein A in agr group IV
strains RN4850 and NRS168. First, we observed that
AP4-24H11 affects the expression and/or secretion of
S. aureus exoproteins, some of which might also be regu-
lated by the agr QS circuits (see Figure S2A). As seen in
Figure 3A, mAb AP4-24H11 can successfully reduce the
a-hemolysin expression in S. aureus; furthermore, no
hemolytic activity was observed on blood agar plates
with the AP4-24H11-treated supernatant (Figure S2B). In
contrast, protein A expression was significantly increased
by mAb AP4-24H11 in RN4850, which is also consistent
with agr QS inhibition.
The only structural difference between AIP-1 and AIP-4
is position 5, and our data suggest that AP4-24H11 is able
to bind to AIP-1 with moderate affinity (z5 mM). Therefore,
we investigated whether AP4-24H11 could affect QS sig-
naling in an agr group I strain, namely Wood 46. Clearly,
AP4-24H11 was not able to block a-hemolysin expression
in Wood 46 as effectively as in RN4850; however, a notable
decrease in a-hemolysin production in Wood 46 grown in
the presence of AP4-24H11 was evident (Figure 3A).
These data suggest that it might be possible to generate
crossreactive mAbs that suppress S. aureus QS signaling
of two or more different agr groups.
Although it could be argued that the decrease in toxin
production and overall protein secretion is caused by an
antibody-mediated growth defect, it is important to note
that no significant growth changes of S. aureus were
observed over a 24 hr growth period in the presence of
AP4-24H11 (Figure 3B). In addition, no discernable
growth effects were observed with mAb SP2-6E11, an
unrelated isotype control (kg2a) for AP4-24H11.
One of the important bacterial virulence factors regu-
lated by QS is biofilm formation. In S. aureus, biofilm for-
mation is known to be negatively regulated by agr QS sig-
naling [29], which is indeed one of the problems in
controlling S. aureus virulence through agr QS inhibition
[30]. Consistent with previous studies, AP4-24H11-medi-
ated QS inhibition led to increased biofilm formation in
RN4850 (Figure 3C). Although the increase of biofilm for-
mation poses a significant problem in chronic infection
of S. aureus, it represents a lesser predicament in acute
infections and, thus, mAb AP4-24H11 might still be an
effective way to control such S. aureus infections.
Real-Time PCR Analysis
To further examine agr QS inhibition by AP4-24H11, we
performed real-time polymerase chain reaction (real-
time PCR) analysis to evaluate whether the observed
changes in virulence factor expression were indeed
caused by interference with the agr QS system, that is,
whether the presence of AP4-24H11 affects the transcrip-
tion of rnaIII, the immediate product of agr autoinduction
and the main QS effector in S. aureus [31]. As expected,
the rnaIII transcriptional level in RN4850 during stationary
growth phase was reduced significantly (>50-fold) by
AP4-24H11; this finding advocates that the alteration of
a-hemolysin and protein A expression is a direct resultChemistry & Biology 14, 1119–1of the interference of AIP-4-mediated QS signaling by
AP4-24H11 (Figure 3D). Yet, the subtle changes in overall
exoprotein expression (see Figure S2A) might be miscon-
strued to mean that AP4-24H11 does not block the QS
signaling efficiently; however, our real-time PCR analysis
provides evidence that AP4-24H11 significantly inhibits
AIP-4-based QS in S. aureus RN4850.
To gain greater appreciation of the specificity and
potential limitations of antibody-based QS interference
in S. aureus, we investigated the transcriptional level of
two additional virulence regulators, namely sarA (staphy-
lococcal accessory regulator) and saeR (staphylococcal
accessory protein effector) [6, 32, 33], which control the
response to environmental stresses as well as virulence
factor expression in S. aureus. Importantly, no significant
changes (%2-fold) were observed in either sarA or saeR
transcription, supporting that AP4-24H11 only affects
the agr QS system (Figure 3D).
The transcription of a-hemolysin and protein A was an-
alyzed by real-time PCR. As stated (vide supra), significant
changes were seen in protein expression level. In terms of
transcription, the hla and spa genes were suppressed and
elevated, respectively, z3- to 5-fold, again confirming
that rnaIII affects not only transcription but also translation
of these proteins, as reported previously [31]. Finally, exo-
foliatin A (eta) transcription was investigated, which is
another agr QS-regulated toxin exclusively produced by
AIP-4 utilizing S. aureus strains [34]. Gratifyingly, our
data indicated that AP4-24H11 also decreased eta tran-
scription byz10-fold (Figure 3D).
Inactivation of AP4-24H11 by the Synthetic AIP-4
Balaban and coworkers have proposed that the RNAIII-
activating protein (RAP) regulates agr QS signaling in
S. aureus in an AIP-independent manner [35]. In addition,
the same group has reported that a linear peptide, termed
RNAIII-inhibiting peptide (RIP), could blunt RAP-mediated
QS signaling, resulting in a decrease in RNAIII transcrip-
tion, although it is still debatable [36, 37]. Although we
have presented evidence that AP4-24H11 inhibited agr
QS through binding to AIP-4 and sequestering it from
the cell growing medium, there was still the possibility
that AP4-24H11 might affect other signaling systems in
S. aureus including RAP, which in turn could affect the
agr QS network. As such, we investigated whether exter-
nal addition of AIP-4 could restore the agr QS signaling
network in S. aureus RN4850 in the presence of AP4-
24H11. Thus, we treated AP4-24H11 with an equimolar
amount of synthetic AIP-4 before addition to the S. aureus
growth medium; this then would assure saturation of the
antibody binding sites with the AIP-4 peptide. As seen in
Figure 3E, the addition of synthetic AIP-4 efficiently re-
duced the quorum quenching effect of AP4-24H11, and
as a result fully restored expression of a-hemolysin in
S. aureus RN4850. As expected, this finding provides ad-
ditional confirmation that AP4-24H11 indeed sequesters
AIP-4 in S. aureus growth medium and inhibits AIP-depen-
dent QS signaling in S. aureus in a strictly AIP-4-depen-
dent manner.127, October 2007 ª2007 Elsevier Ltd All rights reserved 1121
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Anti-Autoinducer AntibodyFigure 3. Inhibition of Quorum Sensing Signaling in S. aureus by AP4-24H11
(A) Western blot analyses of a-hemolysin and protein A expression in S. aureus (RN4850 and Wood 46). S. aureus culture supernatants were prepared
as described in Experimental Procedures.
(B) Relative OD600 (%) of RN4850, NRS168, and Wood 46 after a 20–24 hr incubation in the presence/absence of AP4-24H11.
(C) Analysis of static biofilm formation in RN4850.
(D) Real-time PCR analysis. The amounts of the selected mRNAs were measured in RN4850 grown in the presence or absence of AP4-24H11. Rel-
ative quantification was performed using gyrA as a calibrator. At least two independent experiments were carried out for each experiment in duplicate.
Actual numbers of fold change: rnaIII (77 ± 48), eta (8.1 ± 1), hla (5.2 ± 3.1), spa (+5.7 ± 3.6), sarA (2.1 ± 0.6), and saeR (+1.4 ± 0.4).
(E) Suppression of AP4-24H11-mediated QS inhibition in S. aureus by AIP-4. AP4-24H11 (z1.3 mM) was incubated with the native AIP-4 (2.5 mM) in
CYPG medium for 20 min at room temperature. Overnight cultured S. aureus cells were diluted into the above medium (OD600z 0.03) and grown for
20–24 hr at 37C under the static condition. The supernatants were prepared and analyzed. Error bars indicate the standard deviation (s)) of the
experiment. (For full details, see Experimental Procedures.)AP4-24H11 Inhibits S. aureus-Induced Apoptosis
in Mammalian Cells
Recent studies have shown that incubation of Jurkat T
cells with supernatant of S. aureus culture results in induc-
tion of apoptosis [38]. We treated Jurkat cells with the
supernatants of S. aureus (RN4850 and Wood 46) cultures
grown in the presence or absence of AP4-24H11. After
incubation for 4 hr with the supernatant, the cleavage of
poly(ADP-ribose) polymerase (PARP), a biochemical marker
indicative of apoptosis induction, was evaluated in Jurkat
cell protein extracts. As shown in Figure 4, AP4-24H11
prevented RN4850 supernatant (1%) to induce PARP
cleavage in Jurkat cells, and also partially inhibited the ef-
fect of Wood 46 supernatant. In fact, previous mechanistic
studies proposed that one of the major factors in S. aureus
supernatant responsible for inducing apoptosis might be
a-hemolysin; our findings (Figures 3A and 4), support1122 Chemistry & Biology 14, 1119–1127, October 2007 ª200this positive correlation between expression of a-hemoly-
sin and S. aureus-induced apoptosis.
AP4-24H11 Blocks S. aureus-Induced Dermal
Injury in Mice
Next, we investigated the potential of mAb AP4-24H11 to
mitigate S. aureus-induced injury in vivo by employing
a murine subcutaneous infection model. Freshly grown
log phase S. aureus RN4850 was suspended in PBS con-
taining Cytodex beads and, where indicated, AP4-24H11
or control IgG. Subcutaneous injections of bacterial sus-
pension or vehicle control were made in the flank of
SKH1 hairless mice followed by close monitoring over
7 days. Doses administered were 107 or 108 bacteria (col-
ony forming units; cfu) and 0.6 or 0.06 mg AP4-24H11 or
control IgG. Mice receiving 107 cfu developed minimal hy-
peremia/edema followed by limited induration over 7 days7 Elsevier Ltd All rights reserved
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Anti-Autoinducer AntibodyFigure 4. Inhibition of S. aureus-Induced
PARP Cleavage by AP4-24H11
PARP cleavage in Jurkat cells after treating
with S. aureus (A) RN4850 and (B) Wood 46 su-
pernatants (SN). Human Jurkat leukemic T
cells were maintained in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine
serum, 10 mM L-glutamine, and 50 mg/ml
streptomycin and penicillin (GIBCO, Invitro-
gen). S. aureus supernatants were prepared
as described in Experimental Procedures,
and the supernatants of RN4850 were further
concentrated to one third of the original volume
using Amicon Ultra-4 (5000 NMWL) centrifugal
filter devices (Millipore). Confluent cells were
distributed to 24-well plates in fresh medium
(0.5 ml) and incubated for 6 hr before addition
of the S. aureus supernatants. After a 4 hr incu-
bation with the indicated amount of S. aureus
supernatants, cell extracts were prepared
and analyzed by western blotting using anti-
PARP antibody.(see Figure S3A). However, as early as 6 hr after injection,
mice receiving 108 cfu suspended in saline or control IgG
showed early-stage hyperemia/redness at the injection
site and extending 3–5 mm horizontally and 5–10 mm ver-
tically in a diagonal pattern along the flank (Figure 5A).
Upon reexamination at 18 hr, the same areas surrounding
the injection site were devitalized, and the skin was trans-
formed to a brittle, reddish-brown scab. Over the 7 day
observation period, the hardened scab began to detach
from the surrounding relatively normal appearing skin,
and small amounts of purulent exudate were observed
at the normal/necrotic junction. In contrast, skin injuryChemistry & Biology 14, 1119–1was abrogated in mice that received 108 bacteria with
0.6 mg AP4-24H11 (Figure 5C). As anticipated, the lower
dose of AP4-24H11 (0.06 mg) was not protective (Fig-
ure 5B), and control mice receiving 108 cfu with 0.6 mg
control IgG were not protected (see Figure S3B). Mice
that received an injection of PBS/Cytodex alone or con-
taining 0.6 mg AP4-24H11 remained normal over the ob-
servation period with the exception of occasional local in-
duration (Figure 5D). Excitingly, animals that had received
the protective dose of 0.6 mg AP4-24H11 in combination
with S. aureus RN4850 did not develop any significant
lesions over the 7 day observation period.Figure 5. Inhibition of S. aureus-Induced Abscess Formation by AP4-24H11 in Mice Models
SKH1 euthymic hairless mice (6–8 weeks old) received 200 ml intradermal flank injections containing S. aureus (13 108 bacteria), 4 ml packed volume
Cytodex beads, DPBS, and mAb AP4-24H11 or control IgG (0.06 or 0.6 mg). Additional control animals received 200 ml intradermal injections con-
taining Cytodex beads or beads plus antibody. After injections were made, the mice were monitored at least three times each day over a period of 4–7
days. At the conclusion of the monitoring period, the mice were euthanized and tissues were harvested for bacteriologic and histologic analysis.
(A) S. aureus + PBS.
(B) S. aureus + AP4-24H11 (0.06 mg).
(C) S. aureus + AP4-24H11 (0.6 mg).
(D) Cytodex + AP4-24H11 (0.6 mg).127, October 2007 ª2007 Elsevier Ltd All rights reserved 1123
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Anti-Autoinducer AntibodyPassive Immunization with AP4-24H11 Protects
Mice from S. aureus-Induced Fatality
To evaluate the effectiveness of a passive immunization
approach using AP4-24H11 against a lethal challenge
with S. aureus, SKH1 hairless mice received a 1 ml intra-
peritoneal (i.p.) injection of AP4-24H11, control IgG, or
vehicle (Dulbecco’s phosphate-buffered saline; DPBS)
followed 2 hr later by 0.5 ml DPBS containing 3 3 108
S. aureus RN4850. As shown in Figure 6, all of the mice
receiving AP4-24H11 (6/6) survived through the 8 day
observation period. In contrast, only one of the DPBS-
treated control mice (1/6) and none of the control IgG-
treated mice (0/6) survived longer than 24 hr. These data
further validated our immunopharmacotherapeutic ap-
proach for combating acute S. aureus infections.
SIGNIFICANCE
We have sought to elucidate the consequences of
quorum sensing signaling using highly specific anti-
autoinducer antibodies elicited against a rationally
designed synthetic hapten. Our data indicate that the
scavenging of an AIP by a monoclonal antibody is suf-
ficient to suppress QS-controlled expression of viru-
lence factors in S. aureus, which to our knowledge
establishes this as the first report of AIP removal
from bacterial culture without genetic manipulations
of the organism. Antibodies now comprise over one
third of the molecules undergoing clinical evaluation,
mostly for cancer immunotherapy [39]. However, anti-
body-based therapies for the treatment of bacterial in-
fections using QS as amolecular target are still in their
infancy [39–41]. Conventional QS interference strate-
gies utilizing small-molecule antagonists are based
on a competition between the bacterial autoinducer
Figure 6. Passive Immunization of Mice with AP4-24H11
against S. aureus Infection
Survival in mice that were pretreated with mAb AP4-24H11 or control
IgG followed 2 hr later byS. aureus injection (33 108 i.p.). The numbers
in parentheses show the number of survivors/number per group. Log
rank statistic, p = 0.001; n = 6 for each group.1124 Chemistry & Biology 14, 1119–1127, October 2007 ª2007and the inhibitor for the bacterial AI receptor protein.
In contrast, quorum quenching antibodies engage in
competition with the AI receptor for the autoinducer.
In this context, an immunopharmacotherapeutic strat-
egy is highly appealing, as the antibody acts as a
‘‘decoy-receptor’’ while possessing well-documented
pharmacokinetic behavior and pharmacodynamic
response.
In total, antibodies generated against bacterial
autoinducers represent a new and valuable set of im-
munological tools for both the study of QS-controlled
processes and potentially an alternative strategy en-
gaging immunopharmacotherapy for the prevention
or treatment of infections in which QS signaling con-
tributes to bacterial pathogenesis.
EXPERIMENTAL PROCEDURES
Synthesis of the Linear Protected Peptide 3
All N-a-Fmoc-protected amino acids, coupling reagents, and resins for
peptide synthesis were purchased from EMD Biosciences (San Diego,
CA, USA). All other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA). ESI-MS analyses were performed with API150EX
(PE SCIEX, Foster City, CA, USA), and Hitachi L-7300 (Hitachi, San
Jose, CA, USA) and Shimadzu SCL-10A (Shimadzu, Columbia, MD,
USA) were used for analytical and preparative HPLC experiments,
respectively.
The peptide was synthesized by Fmoc solid-phase peptide synthe-
sis on 2-chlorotrityl resin preloaded with the Fmoc-Met 1. An Fmoc-
Ser(Trt)-OH was incorporated at the position of lactonization. All other
residues were chosen with side-chain protecting groups stable to di-
lute TFA and labile in 95% TFA. A short flexible linker was incorporated
penultimate to the N terminus by coupling Fmoc-8-amino-3,6-diox-
aoctanoic acid. The N-terminal residue was Boc-Cys(SEt)-OH for
eventual use in conjugation to carrier proteins.
Specific Conditions
Batch synthesis was carried out on 1 mmol resin swollen in DMF for at
least 1 hr. A solution of the protected amino acid, N,N0-diisopropylcar-
bodiimide (DIC), and HOBt (4 equivalents each) in 5 ml DMF was pre-
pared and allowed to sit for 5 min for preactivation, followed by the
addition of 0.5 ml sym-collidine. The cocktail was added to the resin
for coupling, which was generally complete in 1 hr. The resin was
then washed with DMF and subjected to Fmoc deprotection with
20% (v/v) piperidine in DMF (2 3 7 min). The resin was then washed
with DMF and the next coupling reaction was carried out. When syn-
thesis was complete, the resin was washed with DMF, then methylene
chloride, and finally with ether before it was placed in a desiccator.
Cleavage (and Trityl Deprotection)
The resin was added to a cocktail of 4% TFA, 4% triisopropylsilane
(TIS), and 0.5% H2O in chloroform, and shaken for 6 hr. The mixture
was filtered, allowing the filtrate to drip into cold ether to precipitate
the peptide. The ether mixture was centrifuged and the supernatant
was decanted. The peptide was then washed (twice) with ether by re-
suspending the solid in ether, centrifuging, and decanting the superna-
tant. The resulting solid was placed in a desiccator.
Purification
The fully protected peptide 3 was dissolved in methylene chloride and
purified by normal-phase silica gel chromatography eluted with 5%
methanol in methylene chloride.
Lactonization of 3
The protected linear peptide 3 was dissolved in 1,2-dichloroethane
(previously dried over anhydrous MgSO4) to give a final concentration
of no greater than 1.0 mM. The solution was stirred and heated to
80C and 3 equivalents each of 1-ethyl-3-(3-dimethylaminopropyl)-Elsevier Ltd All rights reserved
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Anti-Autoinducer Antibodycarbodiimide hydrochloride (EDC) and 4-dimethylaminopyridine (4-
DMAP) were added; another equivalent each of EDC and 4-DMAP
were added at both 24 and 48 hr into the reaction. The reaction was
monitored by HPLC. After 4 days, the reaction mixture was cooled
to room temperature, washed with 2 3 200 ml of 0.2 M KHSO4 (aque-
ous), dried over anhydrous Na2SO4, and evaporated to dryness. The
cyclized peptide 4 was purified by prep-HPLC. Yields ranged from
30%–60% as determined by analytical HPLC integration.
Global Deprotection and Disulfide Deprotection of 4
The solid, purified peptide was dissolved in TFA containing 2% TIS and
stirred for 1 hr. The mixture was then evaporated to dryness. Water
was added and the mixture was frozen and lyophilized. The lyophilized
solid was then dissolved in H2O with tris(2-carboxyethyl)phosphine hy-
drochloride (TCEP). The mixture was stirred for 1 hr and injected di-
rectly into the prep-HPLC for purification, yielding AP4 hapten 5. The
collected pure fractions were pooled, frozen, and lyophilized. ESI-
MS:m/z calculated for C57H80N10O17S2 (M + H), 1241.5; found, 1242.2.
Conjugation of 5 to KLH/BSA
Attachment of Sulfo-SMCC
Five milligrams of the carrier protein was resuspended in 0.9 ml PBS
(pH 7.4). To this solution was added 1 mg of the linker sulfo-SMCC (sul-
fosuccinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate).
The solution was stirred for 6–8 hr and the protein-linker conjugate
was purified by dialysis in PBS at 4C.
Conjugation of the Hapten 5
To the protein-linker conjugate in PBS was added 100 ml DMF contain-
ing 2 mg of the hapten 5. The solution was shaken overnight and the
protein-hapten conjugate was purified by dialysis. MALDI-TOF analy-
sis confirmed the attachment on average of z6 haptens per BSA
molecule.
Analysis of Exoprotein Secretion in S. aureus
After overnight growth on an agar plate at 37C, a single colony of S.
aureus (RN4850 or Wood 46) was inoculated into 3 ml CYGP medium
and grown overnight (18 hr) [42]. The overnight cultured cells were di-
luted to OD600z 0.03 in fresh CYGP medium, and distributed to 5 ml
polystyrene cell-culturing tubes, where each tube contained 0.5 ml of
the diluted cells and the appropriate antibody (0.2 mg/ml). After growth
for 20–24 hr at 37C in a humid incubator without agitation, the sam-
ples were transferred to microcentrifuge tubes (1.5 ml) and centrifuged
at 13,000 rpm for 5 min. The supernatants were sterilized by filtration
through a Millex-GV filter unit (0.22 mm; Millipore, Billerica, MA, USA)
and analyzed by SDS-PAGE (10% bis-Tris gel; Invitrogen, Carlsbad,
CA, USA). To confirm a-hemolysin and protein A expression, western
blot analyses were performed using an HRP-conjugated sheep poly-
clonal a-hemolysin antibody (Abcam, Cambridge, MA, USA) and
anti-protein A mouse monoclonal antibody (Sigma-Aldrich), and mu-
rine mAb SP2-6E11 (J.P. and K.D.J., unpublished data) was used as
a control antibody. To test hemolytic activity, the S. aureus superna-
tants (75 ml 3 3) were applied onto the sheep blood agar plate, and
the plates were incubated at 37C for 18 hr and at room temperature
for another 24 hr.
Static Biofilm Analysis
The biofilm assay was conducted by following a literature procedure
with a few modifications [43]. After S. aureus cells (200 ml) were grown
in tryptic soy broth medium containing 0.2% glucose with or without
the antibody (0.2 mg/ml) in the polystyrene 96-well plate for 20–24 hr
without agitation, the plate was washed by submersion in water and
dried. A crystal violet solution (200 ml, aqueous 0.1%) was added to
stain the biofilm, and then the plate was washed vigorously with water
followed by the addition of acetic acid (250 ml, aqueous 30%) to solu-
bilize the remaining crystal violet. Absorbance was measured at
570 nm with a Spectramax 250 (Molecular Devices, Sunnyvale, CA,
USA).Chemistry & Biology 14, 1119–11Real-Time PCR Analysis
Overnight cultured S. aureus RN4850 cells were diluted to OD600 z
0.03 in fresh CYGP medium (1 ml) containing the antibody and grown
for 20–24 hr (OD600z 2) at 37C without shaking. RNA from the cells
was isolated using an RNeasy mini kit (QIAGEN, Valencia, CA, USA)
according to the manufacturer’s instructions. Isolated RNA was further
purified by treating with RNase-free DNase (QIAGEN) for 30 min at
room temperature. The first-strand DNA was synthesized using the Su-
perScript First-Strand synthesis system for real-time PCR (Invitrogen)
usingz300 ng of purified RNA. Real-time PCR experiments were per-
formed with at least two independent samples, and each experiment
was set up in duplicate using LightCycler FastStart DNA MasterPLUS
SYBR Green I (Roche Applied Science, Indianapolis, IN, USA). Generic
SYBR Green Protocol (Roche) was used for the PCR conditions, and
relative quantification analyses were performed with a LightCycler
2.0 system (Roche Applied Science) using the housekeeping gyrA
gene as a reference. The sequence information of the primers used
in our experiments is listed in Supplemental Data [44].
Dermal Infection Model in Mice
All experiments on mice were performed in accordance with TSRI
guidelines and regulations. SKH1 euthymic hairless mice, 6–8 weeks
old, were obtained from Charles River Laboratories (Wilmington, MA,
USA) and housed in the biocontainment vivarium for 1 week before
use in experiments. Brain heart infusion (BHI) agar was from BBL
(Sparks, MD, USA; 211065), and CYGP broth contained 1% casamino
acids (Fisher, Pittsburgh, PA, USA; BP1424), 1% yeast extract (EMD
Biosciences, San Diego, CA, USA; 1.03753), 0.59% sodium chloride,
0.5% dextrose, and 60 mM b-glycerol phosphate disodium salt (Fluka,
Milwaukee, WI, USA; 50020) as described by Novick [42]. Cytodex 1
beads (GE Healthcare, Piscataway, NJ, USA; 17-0448-01) were sus-
pended (1 g in 50 ml) in Dulbecco’s phosphate-buffered saline without
calcium/magnesium (GIBCO Invitrogen) overnight at 20C. The super-
natant was decanted and the beads were washed three times by sus-
pension in DPBS and 1G sedimentation followed by autoclaving
(121C, 15 psi, 15 min). Staphylococcus aureus RN4850 (AIP-4) was
grown from frozen stock (BHI + 20% glycerol) on BHI agar plates at
35C overnight. Three representative colonies were combined to inoc-
ulate 2 ml CYGP broth, and after overnight incubation without shaking,
0.25 ml of the culture was used to inoculate 5 ml of CYGP followed by
incubation at 35C, 200 rpm for 3 hr. The culture was centrifuged at
1300 3 g at 4C for 20 min, the supernatant was poured off, and the
bacterial pellet was suspended in 1 ml DPBS without calcium/magne-
sium. The SKH1 mice received 200 ml intradermal flank injections con-
taining S. aureus (1 3 107 or 1 3 108 bacteria), 4 ml packed volume
Cytodex beads, DPBS, and anti-AIP-4 antibody or control IgG (0.6 or
0.06 mg). Additional control animals received 200 ml intradermal injec-
tions containing Cytodex beads or beads plus antibody. After the in-
jections were made, the mice were monitored at least three times
each day over a period of 4–7 days. At the conclusion of the monitoring
period, the mice were euthanized and the tissues were harvested for
bacteriologic and histologic analysis.
Passive Immunization of Mice with AP4-24H11
S. aureus RN4850 were stored at 80C in 20% glycerol/BHI medium,
thawed, and grown on BHI agar plates overnight, and three separate
colonies were sampled to inoculate 2 ml CYGP medium. The inoculum
culture was maintained 1 hr at 35C without shaking, followed by shak-
ing at 200 rpm for 3 hr. Aliquots of the freshly grown inoculum culture
were transferred to 5 ml CYGP medium in 50 ml conical polypropylene
tubes (1/20 dilution) followed by shaking at 200 rpm, 35C for 3 hr. The
bacteria were pelleted by centrifugation at 3000 rpm (1300 3 g) for
10 min, 4C. The bacterial pellets were resuspended in Dulbecco’s
phosphate-buffered saline without calcium/magnesium (DPBS) and
enumerated using a Petroff-Hausser counting chamber. Final dilutions
were made in DPBS so that 3 3 108 bacteria were administered i.p.
in 0.5 ml. To maintain viability, bacteria were administered within 2 hr
of harvest.27, October 2007 ª2007 Elsevier Ltd All rights reserved 1125
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Anti-Autoinducer AntibodymAb AP4-24H11, isotype-matched control IgG (1 mg each), or
DPBS was administered i.p. in DPBS to SKH1 mice (6–9 weeks old;
six animals per treatment group) followed 2 hr later by 0.5 ml DPBS
i.p. containing 3 3 108 S. aureus. The mice were monitored several
times on the day of injection and twice each day on subsequent
days, observing ambulation, alertness, response to handling, and
skin temperature measured by infrared thermometry (Raytek Mini-
Temp MT4; Santa Cruz, CA, USA) using a 1 cm diameter infrasternal
skin site. Animals showing surface temperature consistently below
30C and also diminished response to handling and weakened righting
reflex were considered moribund and were euthanized.
Other Experimental Procedures
See the Supplemental Data for details of syntheses of AIPs (also see
Figure S4), competition ELISA, and sequence information of the
primers for real-time PCR.
Supplemental Data
Supplemental Data include four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
http://www.chembiol.com/cgi/content/full/14/10/1119/DC1/.
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